Focal liver lesions detection and characterization: The advantages of gadoxetic acid-enhanced liver MRI

World Journal of Hepatology

Volumn 6, Issue 7, 2014, Pages 477-485

  Palmucci, Stefano ^a  

^a University Hospital 'Policlinico Vittorio Emanuele'   (Italy)

Author keywords

Carcinoma; Gadolinium diethylenetriaminepentaacetic acid; Hepatocellular; Image enhancement; Liver; Magnetic resonance imaging

Indexed keywords

EID: 84905966148     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v6.i7.477     Document Type: Review

References (61)

1. Weinmann HJ, Schuhmann-Giampieri G, Schmitt-Willich H, Vogler H, Frenzel T, Gries H. A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI. Magn Reson Med 1991; 22: 233-237; discussion 242 [PMID: 1812351].
2. Schuhmann-Giampieri G, Schmitt-Willich H, Press WR, Negishi C, Weinmann HJ, Speck U. Preclinical evaluationof Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology 1992; 183: 59-64 [PMID: 1549695 DOI: 10.1148/radiology.183.1.1549695].
3. Clément O, Mühler A, Vexler V, Berthezène Y, Brasch RC. Gadolinium-ethoxybenzyl-DTPA, a new liver-specific magnetic resonance contrast agent. Kinetic and enhancement patterns in normal and cholestatic rats. Invest Radiol 1992; 27: 612-619 [PMID: 1428739].
4. Clément O, Mühler A, Vexler VS, Rosenau W, Berthezène Y, Kuwatsuru R, Brasch RC. Evaluation of radiation-induced liver injury with MR imaging: comparison of hepatocellular and reticuloendothelial contrast agents. Radiology 1992; 185: 163-168 [PMID: 1523301 DOI: 10.1148/radiology.185.1.1523301].
5. Mühler A, Clément O, Vexler V, Berthezène Y, Rosenau W, Brasch RC. Hepatobiliary enhancement with Gd-EOB-DTPA: comparison of spin-echo and STIR imaging for detection of experimental liver metastases. Radiology 1992; 184: 207-213 [PMID: 1609081 DOI: 10.1148/radiology.184.1.1609081].
6. Hammerstingl R, Zangos S, Schwarz W, Rosen T, Bechstein WO, Balzer T, Vogl TJ. Contrast-enhanced MRI of focal liver tumors using a hepatobiliary MR contrast agent: detection and differential diagnosis using Gd-EOB-DTPA-enhanced versus Gd-DTPA-enhanced MRI in the same patient. Acad Radiol 2002; 9 Suppl 1: S119-S120 [PMID: 12019845].
7. Huppertz A, Balzer T, Blakeborough A, Breuer J, Giovagnoni A, Heinz-Peer G, Laniado M, Manfredi RM, Mathieu DG, Mueller D, Reimer P, Robinson PJ, Strotzer M, Taupitz M, Vogl TJ. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 2004; 230: 266-275 [PMID: 14695400 DOI: 10.1148/radiol.2301020269].
8. Ryeom HK, Kim SH, Kim JY, Kim HJ, Lee JM, Chang YM, Kim YS, Kang DS. Quantitative evaluation of liver function with MRI Using Gd-EOB-DTPA. Korean J Radiol 2004; 5: 231-239 [PMID: 15637473].
9. Tamada T, Ito K, Higaki A, Yoshida K, Kanki A, Sato T, Higashi H, Sone T. Gd-EOB-DTPA-enhanced MR imaging: evaluation of hepatic enhancement effects in normal and cirrhotic livers. Eur J Radiol 2011; 80: e311-e316 [PMID: 21315529 DOI: 10.1016/j.ejrad.2011.01.020].
10. Tajima T, Takao H, Akai H, Kiryu S, Imamura H, Watanabe Y, Shibahara J, Kokudo N, Akahane M, Ohtomo K. Relationship between liver function and liver signal intensity in hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging. J Comput Assist Tomogr 2010; 34: 362-366 [PMID: 20498536 DOI: 10.1097/RCT.0b013e3181cd3304].
11. Jeong WK, Kim YK, Song KD, Choi D, Lim HK. The MR imaging diagnosis of liver diseases using gadoxetic acid: emphasis on hepatobiliary phase. Clin Mol Hepatol 2013; 19: 360-366 [PMID: 24459639 DOI: 10.3350/cmh.2013.19.4.360].
12. Kim SH, Jeong WK, Kim Y, Kim MY, Kim J, Pyo JY, Oh YH. Hepatocellular carcinoma composed of two different histologic types: imaging features on gadoxetic acid-enhanced liver MRI. Clin Mol Hepatol 2013; 19: 92-96 [PMID: 23593616 DOI: 10.3350/cmh.2013.19.1.92].
13. Pastor CM, Planchamp C, Pochon S, Lorusso V, Montet X, Mayer J, Terrier F, Vallee JP. Kinetics of gadobenate dimeglumine in isolated perfused rat liver: MR imaging evaluation. Radiology 2003; 229: 119-125 [PMID: 12944603 DOI: 10.1148/radiol.2291020726].
14. Tsuboyama T, Onishi H, Kim T, Akita H, Hori M, Tatsumi M, Nakamoto A, Nagano H, Matsuura N, Wakasa K, Tomoda K. Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging--correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology 2010; 255: 824-833 [PMID: 20501720 DOI: 10.1148/radiol.10091557].
15. Denecke T, Steffen IG, Agarwal S, Seehofer D, Kröncke T, Hänninen EL, Kramme IB, Neuhaus P, Saini S, Hamm B, Grieser C. Appearance of hepatocellular adenomas on gadoxetic acid-enhanced MRI. Eur Radiol 2012; 22: 1769-1775 [PMID: 22437921 DOI: 10.1007/s00330-012-2422-5].
16. Grazioli L, Morana G, Kirchin MA, Schneider G. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology 2005; 236: 166-177 [PMID: 15955857 DOI: 10.1148/radiol.2361040338].
17. Edmondson HA. Tumors of the liver and intrahepatic bile ducts. Washington: Armed Forces Institute of Pathology, 1958
18. Wanless IR, Mawdsley C, Adams R. On the pathogenesis of focal nodular hyperplasia of the liver. Hepatology 1985; 5: 1194-1200 [PMID: 4065824].
19. Shen YH, Fan J, Wu ZQ, Ma ZC, Zhou XD, Zhou J, Qiu SJ, Qin LX, Ye QH, Sun HC, Huang XW, Tang ZY. Focal nodular hyperplasia of the liver in 86 patients. Hepatobiliary Pancreat Dis Int 2007; 6: 52-57 [PMID: 17287167].
20. Bartolozzi C, Cioni D, Donati F, Lencioni R. Focal liver lesions: MR imaging-pathologic correlation. Eur Radiol 2001; 11: 1374-1388 [PMID: 11519546].
21. Maillette de Buy Wenniger L, Terpstra V, Beuers U. Focal nodular hyperplasia and hepatic adenoma: epidemiology and pathology. Dig Surg 2010; 27: 24-31 [PMID: 20357448 DOI: 10.1159/000268404].
22. Grazioli L, Federle MP, Brancatelli G, Ichikawa T, Olivetti L, Blachar A. Hepatic adenomas: imaging and pathologic findings. Radiographics 2001; 21: 877-892; discussion 892-894 [PMID: 11452062 DOI: 10.1148/radiographics.21.4.g01jl04877].
23. Rubin RA, Lichtenstein GR. Hepatic scintigraphy in the evaluation of solitary solid liver masses. J Nucl Med 1993; 34: 697-705 [PMID: 8384256].
24. Boulahdour H, Cherqui D, Charlotte F, Rahmouni A, Dhumeaux D, Zafrani ES, Meignan M. The hot spot hepatobiliary scan in focal nodular hyperplasia. J Nucl Med 1993; 34: 2105-2110 [PMID: 8254396].
25. Zech CJ, Grazioli L, Breuer J, Reiser MF, Schoenberg SO. Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial. Invest Radiol 2008; 43: 504-511 [PMID: 18580333 DOI: 10.1097/RLI.0b013e3181705cd1].
26. Mohajer K, Frydrychowicz A, Robbins JB, Loeffler AG, Reed TD, Reeder SB. Characterization of hepatic adenoma and focal nodular hyperplasia with gadoxetic acid. J Magn Reson Imaging 2012; 36: 686-696 [PMID: 22674623 DOI: 10.1002/jmri.23701].
27. Baranes L, Chiaradia M, Pigneur F, Decaens T, Djabbari M, Zegaï B, Costentin C, Laurent A, Calderaro J, Rahmouni A, Luciani A. Imaging benign hepatocellular tumors: atypical forms and diagnostic traps. Diagn Interv Imaging 2013; 94: 677-695 [PMID: 23830777 DOI: 10.1016/j.diii.2013.05.002].
28. Ronot M, Paradis V, Duran R, Kerbaol A, Vullierme MP, Belghiti J, Valla DC, Vilgrain V. MR findings of steatotic focal nodular hyperplasia and comparison with other fatty tumours. Eur Radiol 2013; 23: 914-923 [PMID: 23064717 DOI: 10.1007/s00330-012-2676-y].
29. Grazioli L, Bondioni MP, Haradome H, Motosugi U, Tinti R, Frittoli B, Gambarini S, Donato F, Colagrande S. Hepatocellular adenoma and focal nodular hyperplasia: value of gadoxetic acid-enhanced MR imaging in differential diagnosis. Radiology 2012; 262: 520-529 [PMID: 22282184 DOI: 10.1148/radiol.11101742].
30. Huppertz A, Haraida S, Kraus A, Zech CJ, Scheidler J, Breuer J, Helmberger TK, Reiser MF. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT--initial observations. Radiology 2005; 234: 468-478 [PMID: 15591431].
31. Lee JM, Zech CJ, Bolondi L, Jonas E, Kim MJ, Matsui O, Merkle EM, Sakamoto M, Choi BI. Consensus report of the4th International Forum for Gadolinium-Ethoxybenzyl- Diethylenetriamine Pentaacetic Acid Magnetic Resonance Imaging. Korean J Radiol 2011; 12: 403-415 [PMID: 21852900 DOI: 10.3348/kjr.2011.12.4.403].
32. Haradome H, Grazioli L, Tinti R, Morone M, Motosugi U, Sano K, Ichikawa T, Kwee TC, Colagrande S. Additional value of gadoxetic acid-DTPA-enhanced hepatobiliary phase MR imaging in the diagnosis of early-stage hepatocellular carcinoma: comparison with dynamic triple-phase multidetector CT imaging. J Magn Reson Imaging 2011; 34: 69-78 [PMID: 21598343 DOI: 10.1002/jmri.22588].
33. Kudo M. Multistep human hepatocarcinogenesis: correlation of imaging with pathology. J Gastroenterol 2009; 44 Suppl 19: 112-118 [PMID: 19148804 DOI: 10.1007/s00535-008-2274-6].
34. Chou CT, Chou JM, Chang TA, Huang SF, Chen CB, Chen YL, Chen RC. Differentiation between dysplastic nodule and early-stage hepatocellular carcinoma: the utility of conventional MR imaging. World J Gastroenterol 2013; 19: 7433-7439 [PMID: 24259975 DOI: 10.3748/wjg.v19.i42.7433].
35. Joo I, Choi BI. New paradigm for management of hepatocellular carcinoma by imaging. Liver Cancer 2012; 1: 94-109 [PMID: 24159577 DOI: 10.1159/000342404].
36. European Association For The Study Of The Liver1; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943 [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001].
37. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236 [PMID: 16250051 DOI: 10.1002/hep.20933].
38. Forner A, Vilana R, Ayuso C, Bianchi L, Solé M, Ayuso JR, Boix L, Sala M, Varela M, Llovet JM, Brú C, Bruix J. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008; 47: 97-104 [PMID: 18069697 DOI: 10.1002/hep.21966].
39. International Consensus Group for Hepatocellular NeoplasiaThe International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009; 49: 658-664 [PMID: 19177576 DOI: 10.1002/hep.22709].
40. Iannicelli E, Di Pietropaolo M, Marignani M, Briani C, Federici GF, Delle Fave G, David V. Gadoxetic acid-enhanced MRI for hepatocellular carcinoma and hypointense nodule observed in the hepatobiliary phase. Radiol Med 2014; 119: 367-376 [PMID: 24297598 DOI: 10.1007/s11547-013-0364-x].
41. Kudo M. Will Gd-EOB-MRI change the diagnostic algorithm in hepatocellular carcinoma? Oncology 2010; 78 Suppl 1: 87-93 [PMID: 20616589 DOI: 10.1159/000315235].
42. Golfieri R, Renzulli M, Lucidi V, Corcioni B, Trevisani F, Bolondi L. Contribution of the hepatobiliary phase of Gd- EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤ 2 cm) HCC in cirrhosis. Eur Radiol 2011; 21: 1233-1242 [PMID: 21293864 DOI: 10.1007/s00330-01 0-2030-1].
43. Kogita S, Imai Y, Okada M, Kim T, Onishi H, Takamura M, Fukuda K, Igura T, Sawai Y, Morimoto O, Hori M, Nagano H, Wakasa K, Hayashi N, Murakami T. Gd-EOB-DTPAenhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow. Eur Radiol 2010; 20: 2405-2413 [PMID: 20490505 DOI: 10.1007/s00330-010-1812-9].
44. Imam K, Bluemke DA. MR imaging in the evaluation of hepatic metastases. Magn Reson Imaging Clin N Am 2000; 8: 741-756 [PMID: 11149677].
45. Dewhurst C, Rosen MP, Blake MA, Baker ME, Cash BD, Fidler JL, Greene FL, Hindman NM, Jones B, Katz DS, Lalani T, Miller FH, Small WC, SudakoffGS, Tulchinsky M, Yaghmai V, Yee J. ACR Appropriateness Criteria pretreatment staging of colorectal cancer. J Am Coll Radiol 2012; 9: 775-781 [PMID: 23122343 DOI: 10.1016/j.jacr.2012.07.025].
46. Lee KH, Lee JM, Park JH, Kim JH, Park HS, Yu MH, Yoon JH, Han JK, Choi BI. MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent gadoxetic acid. Korean J Radiol 2013; 14: 894-904 [PMID: 24265564 DOI: 10.3348/kjr.2013.14.6.894].
47. Baker ME, Pelley R. Hepatic metastases: basic principles and implications for radiologists. Radiology 1995; 197: 329-337 [PMID: 7480672 DOI: 10.1148/radiology.197.2.7480672].
48. Motosugi U, Ichikawa T, Morisaka H, Sou H, Muhi A, Kimura K, Sano K, Araki T. Detection of pancreatic carcinoma and liver metastases with gadoxetic acid-enhanced MR imaging: comparison with contrast-enhanced multi-detector row CT. Radiology 2011; 260: 446-453 [PMID: 21693662 DOI: 10.1148/radiol.11103548].
49. Böttcher J, Hansch A, Pfeil A, Schmidt P, Malich A, Schneeweiss A, Maurer MH, Streitparth F, Teichgräber UK, Renz DM. Detection and classification of different liver lesions: comparison of Gd-EOB-DTPA-enhanced MRI versus multiphasic spiral CT in a clinical single centre investigation. Eur J Radiol 2013; 82: 1860-1869 [PMID: 23932636 DOI: 10.1016/j.ejrad.2013.06.013].
50. Muhi A, Ichikawa T, Motosugi U, Sou H, Nakajima H, Sano K, Sano M, Kato S, Kitamura T, Fatima Z, Fukushima K, Iino H, Mori Y, Fujii H, Araki T. Diagnosis of colorectal hepatic metastases: comparison of contrast-enhanced CT, contrastenhanced US, superparamagnetic iron oxide-enhanced MRI, and gadoxetic acid-enhanced MRI. J Magn Reson Imaging 2011; 34: 326-335 [PMID: 21780227 DOI: 10.1002/jmri.22613].
51. Jeong HT, Kim MJ, Park MS, Choi JY, Choi JS, Kim KS, Choi GH, Shin SJ. Detection of liver metastases using gadoxeticenhanced dynamic and 10-and 20-minute delayed phase MR imaging. J Magn Reson Imaging 2012; 35: 635-643 [PMID: 22095933 DOI: 10.1002/jmri.22880].
52. Saito K, Araki Y, Park J, Metoki R, Katsuyama H, Nishio R, Kakizaki D, Moriyasu F, Tokuuye K. Effect of Gd-EOB-DTPA on T2-weighted and diffusion-weighted images for the diagnosis of hepatocellular carcinoma. J Magn Reson Imaging 2010; 32: 229-234 [PMID: 20578029 DOI: 10.1002/jmri.22219].
53. Morani AC, Elsayes KM, Liu PS, Weadock WJ, Szklaruk J, Dillman JR, Khan A, Chenevert TL, Hussain HK. Abdominal applications of diffusion-weighted magnetic resonance imaging: Where do we stand. World J Radiol 2013; 5: 68-80 [PMID: 23671743 DOI: 10.4329/wjr.v5.i3.68].
54. Lee NK, Kim S, Kim GH, Kim DU, Seo HI, Kim TU, Kang DH, Jang HJ. Diffusion-weighted imaging of biliopancreatic disorders: correlation with conventional magnetic resonance imaging. World J Gastroenterol 2012; 18: 4102-4117 [PMID: 22919242 DOI: 10.3748/wjg.v18.i31.4102].
55. Palmucci S, Mauro LA, Messina M, Russo B, Failla G, Milone P, Berretta M, Ettorre GC. Diffusion-weighted MRI in a liver protocol: its role in focal lesion detection. World J Radiol 2012; 4: 302-310 [PMID: 22900131 DOI: 10.4329/wjr.v4.i7.302].
56. Ichikawa T, Haradome H, Hachiya J, Nitatori T, Araki T. Diffusion-weighted MR imaging with a single-shot echoplanar sequence: detection and characterization of focal hepatic lesions. AJR Am J Roentgenol 1998; 170: 397-402 [PMID: 9456953 DOI: 10.2214/ajr.170.2.9456953].
57. Bruegel M, Rummeny EJ. Hepatic metastases: use of diffusion- weighted echo-planar imaging. Abdom Imaging 2010; 35: 454-461 [PMID: 19471997 DOI: 10.1007/s00261-009-9541-8].
58. Palmucci S, Mauro LA, Failla G, Foti PV, Milone P, Sinagra N, Zerbo D, Veroux P, Ettorre GC, Veroux M. Magnetic resonance with diffusion-weighted imaging in the evaluation of transplanted kidneys: updating results in 35 patients. Transplant Proc 2012; 44: 1884-1888 [PMID: 22974862 DOI: 10.1016/j.transproceed.2012.06.045].
59. Donati OF, Fischer MA, Chuck N, Hunziker R, Weishaupt D, Reiner CS. Accuracy and confidence of Gd-EOB-DTPA enhanced MRI and diffusion-weighted imaging alone and in combination for the diagnosis of liver metastases. Eur J Radiol 2013; 82: 822-828 [PMID: 23287713 DOI: 10.1016/j. ejrad.2012.12.005].
60. Shimada K, Isoda H, Hirokawa Y, Arizono S, Shibata T, Togashi K. Comparison of gadolinium-EOB-DTPA-enhanced and diffusion-weighted liver MRI for detection of small hepatic metastases. Eur Radiol 2010; 20: 2690-2698 [PMID: 20563726 DOI: 10.1007/s00330-010-1842-3].
61. Macera A, Lario C, Petracchini M, Gallo T, Regge D, Floriani I, Ribero D, Capussotti L, Cirillo S. Staging of colorectal liver metastases after preoperative chemotherapy. Diffusionweighted imaging in combination with Gd-EOB-DTPA MRI sequences increases sensitivity and diagnostic accuracy. Eur Radiol 2013; 23: 739-747 [PMID: 22976920 DOI: 10.1007/s00330-012-2658-0]